Restrictive Cardiomyopathy Treatment Market is Likely to Witness Steady Growth by 2033Posted by Ganesh Shinde on April 6th, 2023 The global restrictive cardiomyopathy treatment market is expected to garner a market value of US$ 6.2 Billion in 2023 and is expected to accumulate a market value of US$ 21.05 Billion by registering a CAGR of 13% in the forecast period 2023 to 2033. The market for Restrictive Cardiomyopathy Treatment registered a CAGR of 10% in the historical period 2018 to 2022. The increasing prevalence of heart failures is a major factor driving the market. According to the American Heart Association, around 5.3 million Americans have congestive heart failure within an incidence of 660,000 cases diagnosed yearly this signifies potential of the market. North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced. Furthermore, various start-ups are launching various ways to treat this rare condition. One such start-up is Impulse Dynamics, which is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer CE is FDA approved. Market Competition Key players in the Restrictive Cardiomyopathy Treatment market are Array BioPharma, Vericel Corporation, PhaseBio Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc, Johnson and Johnson, Merck & Co., Inc, Teva Pharmaceuticals, Astrazeneca plc and Sanofi. Read More@ https://www.futuremarketinsights.com/reports/restrictive-cardiomyopathy-treatment-market Key Segments Profiled in the Restrictive Cardiomyopathy Treatment Industry Survey By Type:
By Treatment:
By End User:
Like it? Share it!More by this author |